Evidence map›Paper›PMID 29719440›Full record

SynthesisCurrent oncology (Toronto, Ont.)2018

Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis.

D Tomlinson, P D Robinson, S Oberoi, D Cataudella, N Culos-Reed, H Davis, N Duong, F Gibson, M Götte, P Hinds and 5 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current oncology (Toronto, Ont.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. [Rehabilitative strategies in cancer-related fatigue].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2024
    Review
  11. Article
  12. Article
  13. Review
  14. Management of Fatigue in Patients with Advanced Cancer.Current treatment options in oncology · 2023
    Review
  15. Review
  16. Effects of exercise interventions on cancer-related fatigue in breast cancer patients: an overview of systematic reviews.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

D TomlinsonChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON.
P D RobinsonPediatric Oncology Group of Ontario, Toronto, ON.
S OberoiPediatric Oncology Group of Ontario, Toronto, ON.
D CataudellaDepartment of Pediatric Psychology, Children's Hospital, London Health Sciences Centre, London, ON.
N Culos-ReedFaculty of Kinesiology, University of Calgary, Calgary, AB.
H DavisChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON.
N DuongChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON.
F GibsonCentre for Outcomes and Experiences Research in Children's Health, Illness, and Disability, Great Ormond Street Hospital for Children NHS Foundation Trust, London, and School of Health Sciences, University of Surrey, Guildford, U.K.
M GötteUniversity Hospital Essen, Center for Child and Adolescent Medicine, Department of Pediatric Hematology/Oncology, Essen, Germany.
P HindsDepartment of Nursing Science, Professional Practice, and Quality, Children's National Health System; and Department of Pediatrics, George Washington University, Washington, DC, U.S.A.
S L NijhofDivision of Pediatrics, Wilhelmina Children's Hospital (part of UMC Utrecht), Utrecht, Netherlands.
P van der TorreDivision of Pediatrics, Wilhelmina Children's Hospital (part of UMC Utrecht), Utrecht, Netherlands.
S CabralPediatric Oncology Group of Ontario, Toronto, ON.
L L DupuisChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON.
L SungChild Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON.
Pediatric Oncology Group · CAHospital for Sick Children · CASickKids Foundation · CAUniversity Medical Center Utrecht · NLChildren's National · USEssen University Hospital · DELondon Health Sciences Centre · CAUniversity of Calgary · CAUniversity of Surrey · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Our objective was to determine whether, compared with control interventions, pharmacologic interventions reduce the severity of fatigue in patients with cancer or recipients of hematopoietic stem-cell transplantation (hsct). Methods: For a systematic review, we searched medline, embase, the Cochrane Central Register of Controlled Trials, cinahl, and Psychinfo for randomized trials of systemic pharmacologic interventions for the management of fatigue in patients with cancer or recipients of hsct. Two authors independently identified studies and abstracted data. Methodologic quality was assessed using the Cochrane Risk of Bias tool. The primary outcome was fatigue severity measured using various fatigue scales. Data were synthesized using random-effects models. Results: In the 117 included trials (19,819 patients), the pharmacologic agents used were erythropoietins ( Conclusions: Erythropoietin and methylphenidate significantly reduced fatigue severity in patients with cancer and in recipients of hsct. Concerns about the safety of those agents might limit their usefulness. Future research should identify effective interventions for fatigue that have minimal adverse effects.

Indexed as

Central Nervous System StimulantsErythropoietinFatigueHematopoietic Stem Cell TransplantationHumansMethylphenidateNeoplasmsSeverity of Illness IndexCentral Nervous System StimulantsEPO protein, humanErythropoietinMethylphenidatecancer-related fatiguecorticosteroidsdrugserythropoietinfatiguemeta-analysesPharmacologic agentsstimulants

Identifiers

PMID29719440
PMCPMC5927795
OpenAlexW2802547370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.